Supporting Information

## Identification by Liquid Chromatography–Tandem Mass Spectrometry and Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry of the Contributor to the Thyroid Hormone Receptor Agonist Activity in Effluents from Sewage Treatment Plants

Ryo Omagari <sup>a\*</sup>, Mayuko Yagishita <sup>b</sup>, Fujio Shiraishi <sup>a</sup>, Shoji Nakayama <sup>a</sup>, Masanori Terasaki <sup>c</sup>, Tetsuya Tanigawa <sup>d</sup>, Ichiro Yamauchi <sup>e</sup>, Takuya Kubo <sup>f</sup>, Daisuke Nakajima <sup>a, g</sup>

- <sup>a</sup> Health and Environmental Risk Division, National Institute for Environmental Studies (NIES), Tsukuba-city, Ibaraki, 305-8506, Japan
- <sup>b</sup> Department of Life and Environmental Science, Prefectural University of Hiroshima, Shobara-city, Hiroshima, 727-0023, Japan
- <sup>c</sup> Graduate School of Arts and Sciences, Iwate University, Morioka-city, Iwate, 020-8550, Japan
- <sup>d</sup> Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510, Japan
- <sup>e</sup> Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, 606-8507
- <sup>f</sup> Department of Material Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Nishikyo-ku, Kyoto 615-8510, Japan.
- <sup>g</sup> Graduate School of Pharmaceutical Sciences, Chiba University, Chiba-city, Chiba, 260-8675, Japan

Corresponding author: Ryo Omagari Ph.D.

\*E-mail: <u>omagari.ryo@nies.go.jp</u>

Postal address: Health and Environmental Risk Division, National Institute for Environmental Studies, 16-2 Onogawa, Tsukuba-shi, Ibaraki-ken 305-8506 Japan

## Content overview: 13 Pages, 1 Figure, and 10 Tables

## Summary

Table S1. Geographic coordinates of the sampling sites.	Page S3
Table S2. Characteristics of the water samples.	Page S4
Table S3. Recovery rates of the 13 compounds by the pretreatment.	Page S5
Table S4. MRM of the 13 compounds.	Page S6
Table S5. Instrumental detection limits of the 13 compounds.	Page S7
Table S6. Concentration (ng/L) of the 13 compounds in site 1.	Page S8
Table S7. Concentration (ng/L) of the 13 compounds in site2–site4.	Page S9
Table S8. hTR-agonist activity observed in the sites.	Page S10
Table S9. Concentration (ng-T3 eq/L) of the 13 compounds in site1.	Pages S11–12
Table S10. Concentration (ng-T3 eq/L) of the 13 compounds in site2–site4.	Page S13
Table S11. Fraction experiment results using the HLB column.	Pages S14–15
Figure S1. Dose-response and standard curves by Y2H and LC–MS/MS, respectively.	Page S16
Figure S2. The accurate mass of the main contributor obtained by LC–QTof-MS	Page S17

	Ν	Ε
Site 1	36.084222	140.217028
Site 2	35.634809	139.747504
Site 3	43.066773	141.414372
Site 4	35.596721	139.643595

 Table S1. Geographic coordinates of the sewage treatment plant (STP) sampling sites in the cities of

 Tsuchiura (site1), Minato (site2), Sapporo (site3), and Kawasaki (site4). N = north, E = east.

**Table S2.** Characteristics of the sewage treatment plant effluent samples collected in the cities of Tsuchiura (site1), Minato (site2), and Kawasaki (site4); Temp. and E.C. indicate the temperature and electrical conductivity, respectively. The site1 samples were collected from June 2020 to May 2021, the site2 ones (site2\_Jun. and Sep.) in June 2021 and September 2021, and the site4 one in June 2021.

Site 1	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.
pH	6.7	6.9	6.5	6.9	6.2	7.1
Temp. (°C)	-	24.9	28.9	28.3	24.2	23.0
E.C. (ms/cm)	-	0.44	0.40	0.54	0.50	0.55

Site 1	Dec.	Jan.	Feb.	Mar.	Apr.	May
pH	7.3	6.8	6.5	6.6	7.0	6.9
Temp. (°C)	21.5	18.4	18.8	21.0	21.1	24.9
E.C. (ms/cm)	0.54	0.57	0.54	0.50	0.52	0.70

	Site 2_Jun.	Site 2_Sep.	Site 4
рН	6.7	7.7	8.8
Temp. (°C)	26.6	26.6	23.9
E.C. (ms/cm)	4.6	5.8	0.61

**Table S3.** Recovery rates of the 13 compounds by the pretreatment, calculated as the mean of sevenreplicates. TRIAC=3,3',5-triiodothyroacetic acid; TETRAC=3,3',5,5'-tetraiodothyroacetic acid; GC-1=sobetirome;T3=3,5,3'-triiodothyronine;T4=3,3',5,5'-tetraiodothyronine;DITPA=3,5-diiodothyropropionicacid;3-Cl-T3=3-chloro-3',5,5'-triiodo-L-thyronine;rT3=3,3',5'-triiodo-L-thyronine;Acetyl T4=N-acetyl L-thyroxine;T1=3-iodo-L-thyronine;TCBPA=tetrachlorobisphenol A.

$(\mu g/L)$	1	2	3	4	5	6	7	Average	Recovery rate (%)
TRIAC	18	20	18	21	19	18	17	19	93
TETRAC	14	15	14	16	14	14	13	14	72
GC-1	26	27	26	28	27	25	24	26	130
Т3	17	16	15	16	15	15	15	16	78
T4	18	17	17	18	17	17	17	17	85
DITPA	19	20	19	21	20	19	18	19	97
3-Cl-T3	17	16	16	16	16	16	16	16	80
rT3	27	25	26	27	26	25	25	26	129
Acetyl T4	19	20	20	21	20	19	18	20	99
T1	13	13	13	13	13	10	10	12	60
ТСВРА	22	24	22	23	23	23	22	23	114
TBBPA	23	25	23	25	24	26	24	24	122
Triclabendazole	18	20	18	19	19	17	17	18	91

	Precursor ion	Product ion	Collision energy
TRIAC	576.6	126.7	-40
TETRAC	702.5	126.7	-48
GC-1	327.0	269.1	-32
T3	649.6	126.6	-62
T4	775.5	126.6	-114
DITPA	508.9	126.8	-56
3-Cl-T3	684.5	126.8	-144
rT3	649.6	126.6	-128
Acetyl T4	817.5	126.6	-156
T1	397.9	126.8	-42
ТСВРА	364.9	313.5	-36
TBBPA	542.6	78.5	-110
Triclabendazole	358.8	196.9	-50

**Table S4.** Multiple reaction monitoring (MRM) method of the 13 compounds using LC-MS/MS(Triple Quad 5500+).

**Table S5.** Instrumental detection limits (ag) of the liquid chromatography-tandem mass spectrometry system for the 13 compounds investigated. All the values are represented as the absolute amount in the injection volume (6  $\mu$ L) and were calculated as the mean of seven replicates.

TRIAC	TETRAC	GC-1	T3	<b>T4</b>	DITPA	(22)
12	17	10	14	17	9.3	(ag)
3-Cl-T3	rT3	Acetyl T4	<b>T1</b>	ТСВРА	TBBPA	<b>Triclabendazole</b>
19	30	31	8.6	18	17	3.4

Table S6. Concentration (ng/L), measured via liquid chromatography-tandem mass spectrometry (LC-MS/MS), of the 13 target compounds in the samples collected from the Tsuchiura sewage treatment plant effluents from June 2020 to May 2021 (site1). All the values were calculated as the mean of three replicates. N.D. means below the limit of quantification (LOQ), whose values for the different compounds were as follows: TRIAC = 0.015 ng/L; TETRAC = 0.015 ng/L; GC-1 = 0.015 ng/L; T3 = 0.015 ng/L; T4 = 0.015 ng/L; DITPA = 0.010 ng/L; 3-Cl-T3 = 0.025 ng/L; rT3 = 0.020 ng/L; acetyl T4 = 0.020 ng/L; T1 = 0.015 ng/L; TCBPA = 0.010 ng/L; TBBPA = 0.020 ng/L, triclabendazole = 0.0050 ng/L.

( )				G	0.4	37
(ng/L)	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.
TRIAC	0.46	0.86	1.2	0.88	0.75	1.0
TETRAC	<i>N.D.</i>	<i>N.D.</i>	<i>N.D.</i>	<i>N.D.</i>	<i>N.D.</i>	<i>N.D.</i>
GC-1	<i>N.D.</i>	<i>N.D.</i>	0.0026	<i>N.D.</i>	N.D.	<i>N.D.</i>
T4	N.D.	N.D.	<i>N.D.</i>	N.D.	N.D.	<i>N.D.</i>
Т3	0.0051	0.031	0.037	0.013	0.028	<i>N.D.</i>
DITPA	<i>N.D.</i>	N.D.	<i>N.D.</i>	<i>N.D.</i>	N.D.	N.D.
3-Cl-T3	N.D.	0.050	N.D.	<i>N.D.</i>	<i>N.D.</i>	<i>N.D.</i>
rT3	<i>N.D.</i>	0.031	0.018	0.030	0.014	N.D.
Acetyl T4	<i>N.D.</i>	N.D.	<i>N.D.</i>	<i>N.D.</i>	N.D.	N.D.
T1	0.39	0.50	0.093	0.00024	0.047	0.027
ТСВРА	0.079	0.11	0.19	0.14	0.069	0.089
ТВВРА	0.052	0.076	0.15	0.11	0.055	0.14
Triclabendazole	0.0016	0.095	0.073	0.0030	0.054	<i>N.D.</i>
	Dec.	Jan.	Feb.	Mar.	Apr.	May
TRIAC	0.75	0.71	0.63	0.72	0.59	0.51
TETRAC	<i>N.D.</i>	N.D.	N.D.	N.D.	N.D.	<i>N.D.</i>
GC-1	<i>N.D.</i>	N.D.	N.D.	N.D.	N.D.	<i>N.D.</i>
T4	<i>N.D.</i>	0.019	N.D.	N.D.	N.D.	0.050
Т3	<i>N.D.</i>	0.018	0.018	N.D.	N.D.	0.24
DITPA	<i>N.D.</i>	N.D.	N.D.	N.D.	N.D.	<i>N.D.</i>
3-CI-T3	0.18	0.065	N.D.	N.D.	0.21	N.D.
rT3	0.017	0.037	0.038	N.D.	0.032	N.D.
Acetyl T4	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
- T1	0.29	N.D.	0.23	0.16	0.25	N.D.
ТСВРА	0.059	0.074	0.10	N.D.	0.10	0.030

0.10

0.052

N.D.

0.033

0.0078

0.10

0.032

0.0058

0.030

0.032

N.D.

тсвра

тввра

**Triclabendazole** 

0.059

0.096

N.D.

0.074

0.086

N.D.

**Table S7.** Concentration (ng/L), measured via LC-MS/MS, of the 13 target compounds in the samples collected from Minato (site2) and Sapporo (site3\_EF) sewage treatment plant effluents. The site2 samples were collected in June 2021 and September 2021; the site3 sample was collected in June 2021; the reference water was collected in Kawasaki city (site4) in June 2021. All the values were calculated as the mean of three replicates. N.D. means below the limit of quantification (LOQ), whose values for the different compounds were as follows: TRIAC = 0.015 ng/L; TETRAC = 0.015 ng/L; GC-1 = 0.015 ng/L; T3 = 0.015 ng/L; T4 = 0.015 ng/L; DITPA = 0.010 ng/L; 3-Cl-T3 = 0.025 ng/L; rT3 = 0.020 ng/L; acetyl T4 = 0.020 ng/L; T1 = 0.015 ng/L; TCBPA = 0.010 ng/L; TBBPA = 0.020 ng/L, triclabendazole = 0.0050 ng/L.

(ng/L)	Site 2_Jun.	Site 2_Sep.	Site 3_EF	Site 4
TRIAC	4.2	2.6	0.30	N.D.
TETRAC	0.26	0.43	N.D.	N.D.
GC-1	N.D.	N.D.	0.33	N.D.
T3	N.D.	0.38	N.D.	0.067
T4	0.11	0.41	0.05	0.20
DITPA	N.D.	N.D.	N.D.	N.D.
3-Cl-T3	N.D.	0.49	N.D.	24
rT3	N.D.	0.45	N.D.	0.11
Acetyl T4	N.D.	N.D.	N.D.	N.D.
T1	N.D.	0.17	N.D.	N.D.
ТСВРА	0.11	0.075	0.022	1.0
TBBPA	0.14	0.092	0.12	0.89
Triclabendazole	N.D.	N.D.	N.D.	N.D.

**Table S8.** Human thyroid hormone receptor (hTR) agonist activity in the sewage treatment plant (STP) effluent samples, measured by a yeast two-hybrid assay. The STP samples were collected in the cities of Tsuchiura (site1), Minato (site2), and Sapporo (site3); the reference water samples were collected in Kawasaki city (site4). The site1 samples were collected from June 2020 to May 2021. The site2 ones were collected in June 2021 and September 2021. The site3 and site4 ones were collected in June 2021. N.D. means not detected. All the values are expressed as the T3 equivalent concentration (ng-T3 eq/L).

Site 1_Jun.	Site 1_Jul.	Site 1_Aug.	Site 1_Sep.	Site 1_Oct.	Site 1_Nov.
154	202	252	301	125	214
Site 1_Dec.	Site 1_Jan.	Site 1_Feb.	Site 1_Mar.	Site 1_Apr.	Site 1_May
103	157	111	108	114	133
Site 2_Jun.	Site 2_Sep.	Site 3_EF	Site 4	(ng-T3 eq. /L)	
721	533	65	<i>N.D.</i>		

**Table S9.** Comparison with concentration expressed as equivalent to T3 (ng-T3 eq/L) of the 13 target compounds and the overall hTR-agonist activity (ng-T3 eq/L) in the samples collected from the Tsuchiura STP effluents from June 2020 to May 2021. All values were calculated as the mean of three replicates. N.D. means below the limit of quantification, whose values for the different compounds were as follows (ng-T3 eq./L); TRIAC = 3.1, TETRAC = 1.8, GC-1 = 0.50, T3 = 0.015, T4 = 0.015, DITPA =  $5.7 \times 10^{-3}$ , 3-Cl-T3 =  $8.9 \times 10^{-3}$ ,  $rT3 = 4.9 \times 10^{-3}$ , Acetyl T4 =  $1.4 \times 10^{-3}$ , T1 =  $1.9 \times 10^{-4}$ , TCBPA =  $9.6 \times 10^{-5}$ , TBBPA =  $6.4 \times 10^{-5}$ , Triclabendazole =  $3.7 \times 10^{-6}$ . Y2H is hTR-agonist activity by a yeast two-hybrid assay. TCRs is total contribution rates.

(ng-T3 eq. /L)	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.
TRIAC	93	177	256	179	154	205
TETRAC	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
GC-1	N.D.	N.D.	8.8×10 <sup>-2</sup>	N.D.	N.D.	N.D.
Т3	5.1×10 <sup>-3</sup>	3.1×10 <sup>-2</sup>	3.7×10 <sup>-2</sup>	1.3×10 <sup>-2</sup>	2.8×10 <sup>-2</sup>	N.D.
T4	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
DITPA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
3-Cl-T3	N.D.	1.8×10 <sup>-2</sup>	N.D.	N.D.	N.D.	N.D.
rT3	N.D.	7.5×10 <sup>-3</sup>	4.4×10 <sup>-3</sup>	7.2×10 <sup>-3</sup>	3.3×10 <sup>-3</sup>	N.D.
Acetyl T4	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
T1	4.9×10 <sup>-3</sup>	6.3×10 <sup>-3</sup>	1.2×10 <sup>-3</sup>	3.1×10 <sup>-6</sup>	5.9×10 <sup>-4</sup>	3.4×10 <sup>-4</sup>
ТСВРА	7.6×10 <sup>-4</sup>	1.0×10 <sup>-3</sup>	1.9×10 <sup>-3</sup>	1.3×10 <sup>-3</sup>	6.6×10 <sup>-4</sup>	8.5×10 <sup>-4</sup>
TBBPA	1.7×10 <sup>-4</sup>	2.4×10 <sup>-4</sup>	4.9×10 <sup>-4</sup>	3.6×10 <sup>-4</sup>	1.8×10 <sup>-4</sup>	4.5×10 <sup>-4</sup>
Triclabendazole	1.2×10 <sup>-6</sup>	7.1×10 <sup>-5</sup>	5.5×10 <sup>-5</sup>	2.2×10 <sup>-6</sup>	4.0×10 <sup>-5</sup>	N.D.
Y2H (ng-T3 eq. /L)	154	202	252	301	125	214
TCRs (%)	61	88	102	60	123	96

(ng-T3 eq. /L)	Dec.	Jan.	Feb.	Mar.	Apr.	May
TRIAC	153	145	129	147	121	105
TETRAC	N.D.	N.D.	<i>N.D.</i>	N.D.	N.D.	N.D.
GC-1	N.D.	N.D.	<i>N.D.</i>	N.D.	N.D.	N.D.
Т3	N.D.	1.8×10 <sup>-2</sup>	1.8×10 <sup>-2</sup>	N.D.	N.D.	0.2
T4	N.D.	1.9×10 <sup>-2</sup>	<i>N.D.</i>	N.D.	N.D.	5.0×10 <sup>-2</sup>
DITPA	N.D.	N.D.	<i>N.D.</i>	N.D.	N.D.	N.D.
3-Cl-T3	6.2×10 <sup>-2</sup>	2.3×10 <sup>-2</sup>	<i>N.D.</i>	N.D.	7.3×10 <sup>-2</sup>	N.D.
rT3	4.0×10 <sup>-3</sup>	9.1×10 <sup>-3</sup>	9.3×10 <sup>-3</sup>	N.D.	7.8×10 <sup>-3</sup>	N.D.
Acetyl T4	N.D.	N.D.	<i>N.D.</i>	N.D.	N.D.	N.D.
T1	3.6×10 <sup>-3</sup>	N.D.	2.9×10 <sup>-3</sup>	2.0×10 <sup>-3</sup>	3.2×10 <sup>-3</sup>	N.D.
ТСВРА	5.7×10 <sup>-4</sup>	7.1×10 <sup>-4</sup>	9.6×10 <sup>-4</sup>	N.D.	9.8×10 <sup>-4</sup>	2.9×10 <sup>-4</sup>
TBBPA	3.1×10 <sup>-4</sup>	2.8×10 <sup>-4</sup>	1.7×10 <sup>-4</sup>	1.0×10 <sup>-4</sup>	1.0×10 <sup>-4</sup>	1.0×10 <sup>-4</sup>
Triclabendazole	N.D.	N.D.	N.D.	5.8×10 <sup>-6</sup>	4.3×10 <sup>-6</sup>	<i>N.D.</i>
Y2H (ng-T3 eq. /L)	103	157	111	108	114	133
TCRs (%)	148	92	116	136	106	79

**Table S10.** Comparison with concentration expressed as equivalent to T3 (ng-T3 eq/L) of the 13 target compounds and the overall hTR-agonist activity (ng-T3 eq/L) in the samples collected from the site2, site3, and site4. The site2 samples are STP effluents collected in June 2021 and September 2021; the site3 sample is a STP effluent collected in June 2021; the site4 sample is a reference water collected June 2021. All the values were calculated as the mean of three replicates. N.D. means below the limit of quantification, whose values for the different compounds were as follows (ng-T3 eq. /L); TRIAC = 3.1, TETRAC = 1.8, GC-1 = 0.50, T3 = 0.015, T4 = 0.015, DITPA =  $5.7 \times 10^{-3}$ , 3-Cl-T3 =  $8.9 \times 10^{-3}$ ,  $rT3 = 4.9 \times 10^{-3}$ , Acetyl T4 =  $1.4 \times 10^{-3}$ , T1 =  $1.9 \times 10^{-4}$ , TCBPA =  $9.6 \times 10^{-5}$ , TBBPA =  $6.4 \times 10^{-5}$ , Triclabendazole =  $3.7 \times 10^{-6}$ . Y2H is hTR-agonist activity by a yeast two-hybrid assay. TCRs is total contribution rates.

(ng-T3 eq. /L)	Site 2_Jun.	Site 2_Sep.	Site 3_EF	Site 4
TRIAC	860	533	61	N.D.
TETRAC	32	52	N.D.	N.D.
GC-1	N.D.	N.D.	11	N.D.
T3	N.D.	0.38	N.D.	6.7×10 <sup>-2</sup>
T4	0.11	0.41	5.4×10 <sup>-2</sup>	0.2
DITPA	N.D.	N.D.	N.D.	N.D.
3-Cl-T3	N.D.	0.17	N.D.	8.5
rT3	N.D.	0.11	N.D.	2.7×10 <sup>-2</sup>
Acetyl T4	N.D.	N.D.	N.D.	N.D.
T1	N.D.	2.1×10 <sup>-3</sup>	N.D.	N.D.
ТСВРА	1.1×10 <sup>-3</sup>	7.2×10 <sup>-4</sup>	2.1×10 <sup>-4</sup>	9.6×10 <sup>-3</sup>
TBBPA	4.5×10 <sup>-4</sup>	3.0×10 <sup>-4</sup>	3.8×10 <sup>-4</sup>	2.9×10 <sup>-3</sup>
Triclabendazole	N.D.	N.D.	N.D.	N.D.
Y2H (ng-T3 eq. /L)	721	533	65	-
TCRs (%)	124	110	111	-

**Table S11.** Behavior evaluation of TRIAC and hTR-agonist activity by fractionation using a HLB column (ng-T3 eq/L). All values were calculated as the mean of three replicates. N.D. means below the limit of quantification, whose values for the different compounds were as follows (ng-T3 eq. /L); TRIAC = 3.1, TETRAC = 1.8, GC-1 = 0.50, T3 = 0.015, T4 = 0.015, DITPA =  $5.7 \times 10^{-3}$ , 3-Cl-T3 =  $8.9 \times 10^{-3}$ ,  $rT3 = 4.9 \times 10^{-3}$ , Acetyl T4 =  $1.4 \times 10^{-3}$ , T1 =  $1.9 \times 10^{-4}$ , TCBPA =  $9.6 \times 10^{-5}$ , TBBPA =  $6.4 \times 10^{-5}$ , Triclabendazole =  $3.7 \times 10^{-6}$ . Y2H is hTR-agonist activity by a yeast two-hybrid assay, and N.A. means no activity. TCRs is total contribution rates.

(ng-T3 eq. /L)	MeOH_10%	MeOH_20%	MeOH_30%	MeOH_40%	MeOH_50%	MeOH_60%
TRIAC	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
TETRAC	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
GC-1	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
T4	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
T3	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
DITPA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
3-Cl-T3	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
rT3	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
Acetyl T4	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
T1	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
ТСВРА	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
TBBPA	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
<b>Triclabe ndazole</b>	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
Y2H (ng-T3 eq. /L)	N.A.	N.A.	N.A.	N.A.	<i>N.A.</i>	N.A.
TCRs (%)	-	-	-	-		-

(ng-T3 eq. /L)	MeOH_70%	MeOH_80%	MeOH_90%	MeOH_100%	No fraction
TRIAC	N.D.	N.D.	98	39	124
TETRAC	N.D.	N.D.	N.D.	0.46	N.D.
GC-1	N.D.	N.D.	N.D.	N.D.	N.D.
T4	N.D.	N.D.	N.D.	N.D.	N.D.
T3	N.D.	N.D.	N.D.	N.D.	N.D.
DITPA	N.D.	N.D.	N.D.	N.D.	N.D.
3-Cl-T3	N.D.	N.D.	N.D.	N.D.	N.D.
rT3	N.D.	N.D.	N.D.	N.D.	N.D.
Acetyl T4	N.D.	N.D.	N.D.	N.D.	N.D.
T1	N.D.	N.D.	N.D.	N.D.	N.D.
ТСВРА	N.D.	N.D.	3.4×10 <sup>-4</sup>	2.9×10 <sup>-4</sup>	7.1×10 <sup>-4</sup>
TBBPA	N.D.	N.D.	N.D.	8.0×10 <sup>-5</sup>	1.3×10 <sup>-4</sup>
Triclabendazole	N.D.	N.D.	N.D.	N.D.	N.D.
Y2H (ng-T3 eq. /L)	N.A.	N.A.	260	55	341
TCRs (%)	-	-	38	71	36



Dose-response curve of site 1 (Sep.) by yeast assay

Dose-response curve of site 2 by yeast assay

2

15

6



Figure S1. Dose-response curves by the yeast assay and standard curve by LC-MS/MS. An error bar represents standard errors (n = 3), and some standard errors were smaller than the symbols used to represent the means.



**Figure S2.** Mass spectra measured via liquid chromatography-quadrupole time-of-flight mass spectrometry, including the accurate masses of compounds like TRIAC (indicated by the red arrows), of the STP effluent samples collected in Minato city (site2\_Sep).